Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

46.88
-1.9500-3.99%
Post-market: 46.880.00000.00%18:52 EDT
Volume:881.42K
Turnover:42.17M
Market Cap:2.98B
PE:-20.35
High:49.81
Open:49.25
Low:46.73
Close:48.83
Loading ...

MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position

TIPRANKS
·
27 Feb

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments

TIPRANKS
·
27 Feb

MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements

TIPRANKS
·
26 Feb

MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

MoonLake Immunotherapeutics Q4 Loss Widens

MT Newswires Live
·
26 Feb

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

Benzinga
·
26 Feb

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss

MT Newswires Live
·
26 Feb

MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c)

TIPRANKS
·
26 Feb

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
26 Feb

MoonLake Immunotherapeutics FY EPS USD -1.89

THOMSON REUTERS
·
26 Feb

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
26 Feb

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

Insider Monkey
·
25 Feb

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Pre-Bell|U.S. Futures Extend Gains; MicroStrategy Gains 5%; JD.com Jumps 6%; Nukkleus Soars 60%

Tiger Newspress
·
17 Jan

Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62

MT Newswires Live
·
17 Jan

MoonLake Immunotherap Raised to Buy From Neutral by Goldman Sachs

Dow Jones
·
17 Jan

Positive Outlook for MoonLake Immunotherapeutics: Buy Rating Driven by Promising Trial Results and Strategic Consistency

TIPRANKS
·
17 Jan

MoonLake Immunotherapeutics upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
17 Jan

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

MoonLake Immunotherapeutics: Strategic Expansion in Clinical Trials Positions Sonelokimab for Market Growth

TIPRANKS
·
10 Jan